Brief Report on 3-Weekly Paclitaxel Carboplatin Efficacy in Locally Advanced or Metastatic Squamous Vulvar Cancer

Amant, Frédéric; Nooij, Linda S.; Annibali, Daniela; Rompuy, Anne‐Sophie Van; Han, Sileny; Bulck, Hilde Van den; Goffin, Frédéric

doi:10.1159/000487435

Cited by 12 publications

(11 citation statements)

References 17 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 81 An alternative strategy is the use of neoadjuvant chemotherapy with cisplatin or carboplatin and paclitaxel, to shrink the nodes prior to radiotherapy. 82 …”

Section: Surgical Management Of Vulvar Squamous Cell Carcinomamentioning

confidence: 99%

Cancer of the vulva: 2021 update

Olawaiye

Cuello

Rogers

2021

Intl J Gynecology & Obste

View full text Add to dashboard Cite

Vulvar cancer is an uncommon gynecological malignancy primarily affecting postmenopausal women. There is no specific screening and the most effective strategy to reduce vulvar cancer incidence is the opportune treatment of predisposing and preneoplastic lesions associated with its development. While vulvar cancer may be asymptomatic, most women present with vulvar pruritus or pain, or have noticed a lump or ulcer. Therefore, any suspicious vulvar lesion should be biopsied to exclude invasion. Once established, the most common subtype is squamous cell carcinoma. Treatment of vulvar cancer depends primarily on histology and surgical staging. Treatment is predominantly surgical, particularly for squamous cell carcinoma, although concurrent chemoradiation is an effective alternative, particularly for advanced tumors. Management should be individualized and carried out by a multidisciplinary team in a cancer center experienced in the treatment of these tumors.

show abstract

“… 81 An alternative strategy is the use of neoadjuvant chemotherapy with cisplatin or carboplatin and paclitaxel, to shrink the nodes prior to radiotherapy. 82 …”

Section: Surgical Management Of Vulvar Squamous Cell Carcinomamentioning

confidence: 99%

Cancer of the vulva: 2021 update

Olawaiye

Cuello

Rogers

2021

Intl J Gynecology & Obste

View full text Add to dashboard Cite

show abstract

“…The combination of carboplatin and paclitaxel, as used in other gynaecological malignancies, has been evaluated with or without ifosfamide. Amant et al demonstrated that patients with locally advanced vulvar cancers treated with 3-weekly carboplatin and paclitaxel, responded sufficiently to be able to undergo surgery [ 35 ].…”

Section: Treatment Optionsmentioning

confidence: 99%

Management of Advanced Squamous Cell Carcinoma of the Vulva

Rogers

2021

Cancers

View full text Add to dashboard Cite

Vulvar cancer is a rare gynaecological malignancy, accounting for 2–5% of cancers of the female genital tract. Squamous cell carcinoma is the most frequently occurring subtype and, historically, has been a disease of older post-menopausal women, occurring with a background of lichen sclerosus and other epithelial conditions of the vulvar skin that may be associated with well-differentiated vulvar intra-epithelial neoplasia (dVIN). An increase in human papillomavirus (HPV) infections worldwide has led to an increase in vulvar squamous carcinomas in younger women, resulting from HPV-associated high-grade vulvar squamous intra-epithelial lesions (vHSIL). Surgical resection is the gold standard for the treatment of vulvar cancer. However, as approximately 30% of patients present with locally advanced disease, which is either irresectable or will require radical surgical resection, possibly with a stoma, there has been a need to investigate alternative forms of treatment such as chemoradiation and targeted therapies, which may minimise the psychosexual morbidity of radical surgery. This review aims to provide an update on management strategies for women with advanced vulvar cancer. It is hoped that investigation of the molecular biologies of the two different pathways to vulvar squamous cell carcinoma (HPV-associated and non-HPV-associated) will lead to the development of targeted therapeutic agents.

show abstract

“…We must consider that the reported studies have not adequately assessed the combination of PTX + platinum with or without bevacizumab, which constitute the most used agents in gynecologic malignancies. This protocol was assessed in a small case series of 3 patients published by Amant et al, showing promising results [56]. The potential role of the immune checkpoint inhibitors has been recently evaluated by analyzing the expression of PD-L1, PD-1 and CD8 by immuno-histochemistry [57].…”

Section: Neoadjuvant Chemotherapymentioning

confidence: 99%